| scholarly article | Q13442814 |
| P356 | DOI | 10.1179/1743132814Y.0000000423 |
| P698 | PubMed publication ID | 25033940 |
| P50 | author | Wimrak Onchan | Q57617637 |
| P2093 | author name string | Nipon Chattipakorn | |
| Siriporn C Chattipakorn | |||
| Danop Nanegrungsunk | |||
| P2860 | cites work | Bevacizumab plus irinotecan in recurrent glioblastoma multiforme | Q46942082 |
| Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults | Q46964107 | ||
| A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas | Q48109352 | ||
| Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma | Q48264845 | ||
| Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | Q48479768 | ||
| Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation | Q48568691 | ||
| A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma | Q48810234 | ||
| The Charing Cross Hospital experience with temozolomide in patients with gliomas | Q48836301 | ||
| Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells | Q49013629 | ||
| AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. | Q55463295 | ||
| Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. | Q55478945 | ||
| Assumptions in the radiotherapy of glioblastoma | Q55490810 | ||
| β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma | Q24564890 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis | Q44661518 | ||
| Initial chemotherapy in gliomatosis cerebri. | Q44995794 | ||
| Salvage therapy with single agent bevacizumab for recurrent glioblastoma. | Q45931836 | ||
| The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. | Q46016867 | ||
| Bevacizumab and irinotecan for recurrent oligodendroglial tumors. | Q46025900 | ||
| Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours | Q46230407 | ||
| Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma | Q46240831 | ||
| Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. | Q46294074 | ||
| Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival | Q46332916 | ||
| Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme | Q46412809 | ||
| Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases | Q46451671 | ||
| Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results | Q46468735 | ||
| Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study | Q46616816 | ||
| Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors | Q46712950 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group | Q30584392 | ||
| Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse | Q30647642 | ||
| Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence | Q31148416 | ||
| Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma | Q33358831 | ||
| Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 | ||
| Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma | Q33384898 | ||
| Bevacizumab and daily temozolomide for recurrent glioblastoma | Q33396384 | ||
| Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma | Q33397569 | ||
| Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. | Q33398201 | ||
| Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study | Q33398291 | ||
| Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial | Q33401179 | ||
| Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial | Q33453675 | ||
| Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production | Q34023873 | ||
| A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival | Q34108339 | ||
| First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience | Q34116001 | ||
| Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study | Q34239497 | ||
| Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain | Q34400848 | ||
| Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 | ||
| Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma | Q34562175 | ||
| Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage | Q34576873 | ||
| Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience | Q34591396 | ||
| Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma | Q34621127 | ||
| Multifocal glioblastoma multiforme: prognostic factors and patterns of progression | Q34627972 | ||
| Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells | Q34632817 | ||
| Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme | Q34679133 | ||
| Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy | Q35008766 | ||
| The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma | Q35053326 | ||
| Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study | Q35570253 | ||
| State-of-the-art treatment of high-grade brain tumors | Q35650039 | ||
| Emerging insights into the molecular and cellular basis of glioblastoma | Q35914897 | ||
| Current management of glioblastoma multiforme | Q35924433 | ||
| Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy | Q36007805 | ||
| Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells | Q36026945 | ||
| Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients | Q36306504 | ||
| Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents | Q36395924 | ||
| Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma | Q36416218 | ||
| Radiation dose-volume effects in the brain. | Q36560171 | ||
| A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | Q36621800 | ||
| Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. | Q36671738 | ||
| Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma | Q36804867 | ||
| Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. | Q36867831 | ||
| Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas | Q36900428 | ||
| Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model | Q36982114 | ||
| Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety | Q37148350 | ||
| Glioma extent of resection and its impact on patient outcome | Q37170201 | ||
| Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience | Q37180426 | ||
| Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | Q37356520 | ||
| Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab | Q37395361 | ||
| Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). | Q37526275 | ||
| 2007 World Health Organization classification of tumours of the central nervous system | Q37645441 | ||
| Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation | Q37953862 | ||
| Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? | Q38074263 | ||
| Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study | Q38481449 | ||
| Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma | Q39225065 | ||
| Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype | Q39281709 | ||
| Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway | Q39359487 | ||
| In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma | Q39370721 | ||
| Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma | Q39374075 | ||
| Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments. | Q39394543 | ||
| Temozolomide: mechanisms of action, repair and resistance | Q39436413 | ||
| Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy | Q39441346 | ||
| Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. | Q39720269 | ||
| Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin | Q40278340 | ||
| Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells | Q40600919 | ||
| Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide | Q40602396 | ||
| Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids | Q42560730 | ||
| Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study | Q43121697 | ||
| NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide | Q43245397 | ||
| Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. | Q43573420 | ||
| The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy | Q43719540 | ||
| Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens | Q43892965 | ||
| Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme | Q43899658 | ||
| Radiotherapy with and without temozolomide in elderly patients with glioblastoma | Q44220822 | ||
| Glioma-associated endothelial cells are chemoresistant to temozolomide | Q44633285 | ||
| P433 | issue | 2 | |
| P921 | main subject | bevacizumab | Q413299 |
| temozolomide | Q425088 | ||
| P304 | page(s) | 167-183 | |
| P577 | publication date | 2014-07-18 | |
| P1433 | published in | Neurological Research | Q15765622 |
| P1476 | title | Current evidence of temozolomide and bevacizumab in treatment of gliomas | |
| P478 | volume | 37 |
| Q41613928 | All-trans retinoic acid enhances temozolomide-induced autophagy in human glioma cells U251 via targeting Keap1/Nrf2/ARE signaling pathway |
| Q52644558 | An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective. |
| Q64077485 | Analysis of the Factors Affecting the Prognosis of Glioma Patients |
| Q46563593 | Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors. |
| Q30930526 | Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors |
| Q38791893 | Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells. |
| Q38703907 | Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines |
| Q97692527 | Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells |
| Q41684309 | Difference in the Inhibitory Effect of Temozolomide on TJ905 Glioma Cells and Stem Cells |
| Q47258480 | Functional network analysis of gene-phenotype connectivity associated with temozolomide |
| Q57485200 | H19 induced by oxidative stress confers temozolomide resistance in human glioma cells via activating NF-κB signaling |
| Q39174318 | Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. |
| Q91828837 | Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma Cells |
| Q91774056 | Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux |
| Q94555289 | Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide |
| Q36051028 | Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review |
| Q45862300 | Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release |
| Q57153312 | Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma |
| Q28066270 | Targeting autophagy to sensitive glioma to temozolomide treatment |
| Q64122872 | Targeting off-target effects: endoplasmic reticulum stress and autophagy as effective strategies to enhance temozolomide treatment |
Search more.